Contineum Therapeutics said the MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 as a monotherapy did not meet its primary efficacy endpoint in major depressive disorder. The treatment was well-tolerated with no new safety signals, while Johnson & Johnson continues reviewing exploratory data to determine next steps for the program.

Key Highlights

  • Johnson & Johnson is assessing prespecified exploratory endpoints and the clinical relevance of the findings.
  • MOONLIGHT-1 Phase 2 trial failed to achieve its primary efficacy endpoint.
  • The monotherapy study assessed JNJ-5120/PIPE-307 in adults with major depressive disorder.
  • Reported tolerability included no new safety signals; Johnson & Johnson is evaluating further data.

Contineum Therapeutics, Inc. (NASDAQ: CTNM) said its MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 in major depressive disorder failed to achieve its primary efficacy endpoint. The result concerns a monotherapy study in adult participants, while the treatment’s reported safety profile included no new safety signals.

Primary Efficacy Goal Not Achieved

The trial assessed the medicine in adults with major depressive disorder. Contineum said the study did not meet that efficacy goal. Trial information is available through ClinicalTrials.gov under NCT 06785012.

Johnson & Johnson Reviews Further Data

Johnson & Johnson continues to evaluate the study results, including prespecified exploratory endpoints. The reported tolerability outcome included no new safety signals. Contineum Therapeutics said the program remains subject to Johnson & Johnson’s evaluation of the trial data and potential next steps.